Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 4 Study of YUTIQ (Fluocinolone Acetonide Intravitreal Implant) 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (Intraocular Inflammation Study)

Next Previous
Trial Profile

Phase 4 Study of YUTIQ (Fluocinolone Acetonide Intravitreal Implant) 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (Intraocular Inflammation Study)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Posterior uveitis
  • Focus Therapeutic Use
  • Acronyms SYNCHRONICITY
  • Sponsors Alimera Sciences; EyePoint Pharmaceuticals

Most Recent Events

  • 04 Jan 2024 Status changed from recruiting to active, no longer recruiting, according to an Alimera Sciences media release.
  • 04 Jan 2024 According to an Alimera Sciences media release, company announced completion of enrollment of Synchronicity Study. Initial readout from this study in the second half of next year.
  • 26 Oct 2023 Planned primary completion date changed from 1 Sep 2024 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top